Related references
Note: Only part of the references are listed.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia
Wanda Salzer et al.
LEUKEMIA & LYMPHOMA (2018)
From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education
Deborah Woods et al.
JOURNAL OF PEDIATRIC ONCOLOGY NURSING (2017)
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
Lynda M. Vrooman et al.
PEDIATRIC BLOOD & CANCER (2016)
Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada
Tamara MacDonald et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2016)
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance
Troy Z. Horvat et al.
LEUKEMIA RESEARCH (2016)
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
Andrew E. Place et al.
LANCET ONCOLOGY (2015)
Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review
Lesleigh S. Abbott et al.
PEDIATRIC DRUGS (2015)
PEG-Asparaginase Allergy in Children With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Protocol
Louise Tram Henriksen et al.
PEDIATRIC BLOOD & CANCER (2015)
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
Wing H. Tong et al.
BLOOD (2014)
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies
Christian A. Fernandez et al.
BLOOD (2014)
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4
Anne L. Angiolillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Hyperammonemia secondary to asparaginase: A case series
Vicki Nussbaum et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group
Wanda L. Salzer et al.
BLOOD (2013)
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia
C. Liu et al.
LEUKEMIA (2012)
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
Meir Wetzler et al.
BLOOD (2007)
Clinical pharmacology of asparaginases in the United States: Asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients
Vassilios I. Avramis et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse:: A children's oncology group study (CCG-1941)
Mohammad Jarrar et al.
PEDIATRIC BLOOD & CANCER (2006)
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - The past, the present and recommendations for the future
VI Avramis et al.
CLINICAL PHARMACOKINETICS (2005)
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
LB Silverman et al.
BLOOD (2001)
Share Paper
